Clinical Significance and Prognostic Value of Receptor Conversion in Hormone Receptor Positive Breast Cancers After Neoadjuvant Chemotherapy

World Journal of Surgical Oncology - United Kingdom
doi 10.1186/s12957-018-1332-7
Full Text
Abstract

Available in full text

Categories
SurgeryOncology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Impact of Molecular Subtype Conversion of Breast Cancers After Neoadjuvant Chemotherapy on Clinical Outcome

Cancer Research and Treatment
Cancer ResearchOncology
2016English

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Clinical Benefit From Neoadjuvant Chemotherapy in Oestrogen Receptor-Positive Invasive Ductal and Lobular Carcinomas

British Journal of Cancer
Cancer ResearchOncology
2013English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy

Targeted Oncology
Cancer ResearchOncologyPharmacology
2018English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Progesterone Receptor Expression in Proliferating Cancer Cells of Hormone-Receptor-Positive Breast Cancer

Tumor Biology
MedicineCancer Research
2018English

Risk of Second Breast Cancers After Lobular Carcinoma in Situ According to Hormone Receptor Status

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy